{"schema_version":"secwatch.filing_event.v1","accession":"0001764013-25-000037","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2025-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.780549+00:00","generated_at":"2026-05-24T11:56:19.245357+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Batoclimab meets MG Phase 3 primary endpoint; CIDP shows 84% responder rate with >70% IgG reduction","bullets":["MG Phase 3: 680mg batoclimab arm achieved 5.6-point MG-ADL improvement vs 3.6 placebo (p<0.001).","Minimal Symptom Expression (MSE) at Week 12: 42% for 680mg, 31% for 340mg, 7% placebo.","CIDP Phase 2b Period 1: 1.8-point aINCAT improvement; 84% responder rate among patients with ≥70% IgG reduction.","Company will not seek batoclimab approval in MG/CIDP; focusing on IMVT-1402 and awaiting thyroid eye disease data.","IND cleared for IMVT-1402 in MG and CIDP; registrational studies expected to start imminently."],"urls":{"canonical":"https://secwatch.observer/filing/0001764013-25-000037","json":"https://secwatch.observer/filing/0001764013-25-000037.json","markdown":"https://secwatch.observer/filing/0001764013-25-000037.md","text":"https://secwatch.observer/filing/0001764013-25-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000176401325000037/0001764013-25-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000176401325000037/imvt-20250319.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T11:56:19.245357+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}